CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)
CapsoVision (CV) reported Preferred Stock Liabilities of $143.6 million for Q2 2025, up 11.66% on a YoY basis from $128.6 million in Q2 2024, and little changed sequentially from $143.6 million in Q4 2024.
CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
CapsoVision (CV) has 2 years of Preferred Stock Liabilities data on file, last reported at $143.6 million in Q2 2025.
- For the quarter ending Q2 2025, Preferred Stock Liabilities rose 11.66% year-over-year to $143.6 million; the trailing twelve-month figure through Jun 2025 stood at $143.6 million (up 11.66% YoY), and the FY2024 full-year result was $143.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $143.6 million in Q2 2025, from $143.6 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $143.6 million in Q4 2024 to a low of $128.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | CapsoVision | 162.07 Mn | 151.95 Mn | 1.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143.63 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 138.63 Mn |
| Jun 30, 2024 | 128.63 Mn |